Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAC Arctos NorthStar Acquisition	$10.19	$9.75	$9.44 ▼ $10.20	$402.81M	N/A	53,611 shs	705 shs
DVAX Dynavax Technologies	$10.52 -4.0%	$10.60	$9.22 ▼ $14.63	$1.23B	1.09	2.08 million shs	2.40 million shs
INVA Innoviva	$20.08 +0.5%	$19.73	$16.67 ▼ $22.00	$1.26B	0.38	824,348 shs	306,117 shs
NVAX Novavax	$7.87 +3.2%	$7.28	$5.01 ▼ $15.22	$1.28B	2.5	6.74 million shs	6.90 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAC Arctos NorthStar Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
DVAX Dynavax Technologies	+5.09%	+3.11%	-2.06%	+11.73%	-3.78%
INVA Innoviva	+0.10%	-4.36%	+3.58%	+5.27%	+7.65%
NVAX Novavax	-12.70%	-19.09%	+5.68%	+5.24%	-41.04%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANAC Arctos NorthStar Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	4.5323 of 5 stars	3.3	2.0	0.0	4.7	3.3	1.7	1.9
INVA Innoviva	4.5057 of 5 stars	3.5	1.0	0.0	4.2	3.9	1.7	1.9
NVAX Novavax	4.628 of 5 stars	3.1	2.0	0.0	4.7	3.0	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAC Arctos NorthStar Acquisition	0.00	N/A	N/A	N/A
DVAX Dynavax Technologies	2.50	Moderate Buy	$24.33	131.42% Upside
INVA Innoviva	3.00	Buy	$42.75	112.91% Upside
NVAX Novavax	2.13	Hold	$15.57	97.81% Upside

Current Analyst Ratings Breakdown

Latest ANAC, NVAX, INVA, and DVAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$32.00
8/20/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform	$9.00 ➝ $7.00
8/11/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
8/11/2025	INVA Innoviva	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
8/8/2025	DVAX Dynavax Technologies	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$31.00 ➝ $32.00
7/22/2025	NVAX Novavax	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/14/2025	INVA Innoviva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
7/11/2025	INVA Innoviva	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$26.00
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAC Arctos NorthStar Acquisition	N/A	N/A	$0.18 per share	56.23	($0.63) per share	N/A
DVAX Dynavax Technologies	$277.25M	4.45	$0.16 per share	65.80	$4.21 per share	2.50
INVA Innoviva	$358.71M	3.53	$3.45 per share	5.82	$11.34 per share	1.77
NVAX Novavax	$682.16M	1.87	N/A	N/A	$0.23 per share	34.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAC Arctos NorthStar Acquisition	$7.16M	N/A	0.00	∞	N/A	N/A	-70.78%	3.97%	N/A
DVAX Dynavax Technologies	$27.31M	-$0.46	N/A	21.46	N/A	-16.67%	5.10%	3.00%	11/6/2025 (Estimated)
INVA Innoviva	$23.39M	$0.31	64.71	12.95	N/A	10.44%	18.67%	9.92%	11/5/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.28	3.45	98.40	0.10	39.20%	-142.33%	28.65%	N/A

Latest ANAC, NVAX, INVA, and DVAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DVAX Dynavax Technologies	$0.12	$0.14	+$0.02	$0.14	$87.55 million	$95.44 million
8/6/2025	Q2 2025	INVA Innoviva	$0.57	$0.77	+$0.20	$0.77	$87.10 million	$100.28 million
8/6/2025	Q2 2025	NVAX Novavax	-$0.07	$0.62	+$0.69	$0.62	$149.19 million	$239.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAC Arctos NorthStar Acquisition	N/A	N/A	N/A	N/A	N/A
DVAX Dynavax Technologies	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAC Arctos NorthStar Acquisition	N/A	0.15	0.15
DVAX Dynavax Technologies	0.45	6.65	6.01
INVA Innoviva	0.36	2.64	2.44
NVAX Novavax	5.93	2.36	2.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAC Arctos NorthStar Acquisition	71.06%
DVAX Dynavax Technologies	96.96%
INVA Innoviva	99.12%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
ANAC Arctos NorthStar Acquisition	N/A
DVAX Dynavax Technologies	2.98%
INVA Innoviva	2.25%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAC Arctos NorthStar Acquisition	N/A	39.53 million	N/A	Not Optionable
DVAX Dynavax Technologies	350	117.27 million	113.77 million	Optionable
INVA Innoviva	100	63.02 million	61.60 million	Optionable
NVAX Novavax	1,990	162.42 million	160.80 million	Optionable

ANAC, NVAX, INVA, and DVAX Headlines

Recent News About These Companies

Bank of America Reiterates Underperform Rating for Novavax (NASDAQ:NVAX)

August 22 at 8:48 AM | marketbeat.com

Novavax Announces $225M Convertible Senior Notes Issuance

August 21 at 8:51 AM | tipranks.com

Novavax announces convertible debt refinancing

August 21 at 8:10 AM | seekingalpha.com

Novavax Announces Convertible Debt Refinancing

August 21 at 7:43 AM | prnewswire.com

Fox Run Management L.L.C. Invests $479,000 in Novavax, Inc. $NVAX

August 21 at 4:08 AM | marketbeat.com

B of A Securities Downgrades Novavax (NVAX)

August 20 at 8:35 PM | msn.com

Stock Traders Buy Large Volume of Novavax Call Options (NASDAQ:NVAX)

August 20 at 3:46 PM | marketbeat.com

BofA downgrades Novavax stock on vaccine uncertainty

August 20 at 3:34 PM | in.investing.com

Novavax downgraded to Underperform from Neutral at BofA

August 20 at 3:34 PM | msn.com

Nu double upgraded, Novavax downgraded: Wall Street's top analyst calls

August 20 at 3:34 PM | finance.yahoo.com

Novavax downgraded to Underperform at BofA on growth uncertainties

August 20 at 3:34 PM | msn.com

Novavax (NASDAQ:NVAX) Shares Gap Up - Should You Buy?

August 20 at 1:21 PM | marketbeat.com

Entropy Technologies LP Invests $191,000 in Novavax, Inc. (NASDAQ:NVAX)

August 18, 2025 | marketbeat.com

Novavax (NASDAQ:NVAX) Trading 5.4% Higher - Here's What Happened

August 16, 2025 | marketbeat.com

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

August 13, 2025 | zacks.com

Novavax (NASDAQ:NVAX) Trading Down 5.7% - Here's Why

August 12, 2025 | marketbeat.com

B. Riley Comments on Novavax's FY2027 Earnings (NASDAQ:NVAX)

August 12, 2025 | marketbeat.com

XTX Topco Ltd Buys Shares of 67,803 Novavax, Inc. (NASDAQ:NVAX)

August 10, 2025 | marketbeat.com

Novavax Stock Surges Amid Strategic Gains

August 10, 2025 | msn.com

FDA reinstates top vaccines regulator just days after his abrupt departure

August 9, 2025 | msn.com

TD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)

August 8, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANAC, NVAX, INVA, and DVAX Company Descriptions

Arctos NorthStar Acquisition NASDAQ:ANAC

Arctos NorthStar Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It focuses on sports, media, and entertainment sectors. The company was founded in 2020 and is based in Dallas, Texas.

Dynavax Technologies NASDAQ:DVAX

$10.52 -0.44 (-3.97%)

As of 03:48 PM Eastern

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Innoviva NASDAQ:INVA

$20.08 +0.11 (+0.55%)

As of 03:47 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Novavax NASDAQ:NVAX

$7.87 +0.24 (+3.17%)

As of 03:48 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time